fda warning letter hims & hers compounded semaglutide september 2025 Health addresses scrutiny of GLP-1 compounding| STAT There's lots going on this

Notable for: Multi-database design (improves generalizability) Active comparator framework Emphasis on short-term safety with acknowledgment of need for longer follow-up Diabetes Care Retrospective Cohort Evaluated thyroid tumors (broader outcome than confirmed malignancies) and found no increased risk with GLP-1 RA exposure in type 2 diabetes patients initiating second-line treatments

Others will simply ask you to discard it

Olausson EA, Storsrud S, Grundin H, Isaksson M, Attvall S, Simren M

Sinai Hospital, who provided an overview of the known and potential AEs of GLP-1-based therapies

PMID: 32523467 [PMC free article] [PubMed] [Google Scholar] 24.Ferraz RR, Tiselius HG, Heilberg IP